Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA ®, ALPROLIX®)

Conditions: Hemophilia A; Hemophilia B Interventions: Drug: Describe the respective haemostatic efficacy of Elocta ® for haemopilia A during surgical procedures; Drug: Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures Sponsors: Hospices Civils de Lyon Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials